Further resolution of non-T2 asthma subtypes from high-throughput sputum transciptomics data in U-BIOPRED

N. Zounemat Kermani (London, United Kingdom), S. Pavlidis (London, United Kingdom), M. Saqi (London, United Kingdom), Y. Guo (London, United Kingdom), P. Agapow (London, United Kingdom), C. Kuo (London, United Kingdom), M. Loza (Springhouse, United States of America), F. Baribaud (Springhouse, United States of America), A. Rowe (Springhouse, United States of America), A. Sousa (Stockley Park, United Kingdom), B. De Meulder (Lyon, France), D. Lefaudeux (Lyon, France), L. Fleming (London, United Kingdom), J. Corfield (Nottingham, United Kingdom), R. Knowles (Stevenage, United Kingdom), C. Auffray (Lyon, France), R. Djukanovic (Southampton, United Kingdom), P. Sterk (Amsterdam, Netherlands), I. Adcock (London, United Kingdom), F. Chung (London, United Kingdom)

Source: International Congress 2018 – Innovative therapies in asthma and COPD
Session: Innovative therapies in asthma and COPD
Session type: Poster Discussion
Number: 606
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Zounemat Kermani (London, United Kingdom), S. Pavlidis (London, United Kingdom), M. Saqi (London, United Kingdom), Y. Guo (London, United Kingdom), P. Agapow (London, United Kingdom), C. Kuo (London, United Kingdom), M. Loza (Springhouse, United States of America), F. Baribaud (Springhouse, United States of America), A. Rowe (Springhouse, United States of America), A. Sousa (Stockley Park, United Kingdom), B. De Meulder (Lyon, France), D. Lefaudeux (Lyon, France), L. Fleming (London, United Kingdom), J. Corfield (Nottingham, United Kingdom), R. Knowles (Stevenage, United Kingdom), C. Auffray (Lyon, France), R. Djukanovic (Southampton, United Kingdom), P. Sterk (Amsterdam, Netherlands), I. Adcock (London, United Kingdom), F. Chung (London, United Kingdom). Further resolution of non-T2 asthma subtypes from high-throughput sputum transciptomics data in U-BIOPRED. 606

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
High-throughput analysis of induced sputum from the U-BIOPRED study using novel proteomic and data mining approaches
Source: Annual Congress 2013 –Origins and diagnosis of asthma
Year: 2013



Sputum proteomics identifies distinct endotypes of exacerbations in bronchiectasis
Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers
Year: 2020


U-BIOPRED accessible handprint: combining omics platforms to identify stable asthma subphenotypes
Source: International Congress 2018 – Biomarkers in COPD and asthma
Year: 2018



Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis
Source: Eur Respir J, 51 (5) 1702173; 10.1183/13993003.02173-2017
Year: 2018



Integration of multi-omics datasets enables molecular classification of COPD
Source: Eur Respir J, 51 (5) 1701930; 10.1183/13993003.01930-2017
Year: 2018



Metabolomic profiling differences among asthma, COPD and healthy controls: a LC-MS-based metabolomics analysis
Source: International Congress 2019 – Evaluation of basic science in airway diseases
Year: 2019

Integrating fingerprints: molecular phenotyping of severe asthma
Source: International Congress 2015 – Fingerprinting severe asthma
Year: 2015



Non-targeted integrative multi-omics approaches on sputum reveal potential diagnostic and monitoring biomarkers for respiratory diseases
Source: International Congress 2017 – Novel molecular and genetic targets in COPD
Year: 2017

Eicosanoids in asthma: multi-omics data interpretation
Source: ERS Lung Science Conference 2016
Year: 2016

Genetics, genomics and a systems approach to asthma
Source: Annual Congress 2008 - “Omics” and systems biology: the promise of future disease understanding
Year: 2008


Deconvolution of the sputum transcriptome and methylome by quadratic programming in asthma and COPD
Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease
Year: 2021


Unbiased cluster analysis of severe asthma based on metabolomics by the U-BIOPRED electronic nose platform
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013


GC MS based untargeted metabolomics for understanding the pathophysiology of asthma COPD overlap (ACO)
Source: International Congress 2018 – Biomarkers of COPD and asthma-COPD overlap syndrome (ACOS)
Year: 2018




“Integrative microbiomics” reveals a disrupted interactome in bronchiectasis exacerbations
Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy
Year: 2020




Endotyping bronchiectasis through multi-omic profiling
Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy
Year: 2020




The six-gene expression signature in whole sampled sputum provides clinically feasible inflammatory phenotyping of asthma
Source: ERJ Open Res, 6 (1) 00280-2019; 10.1183/23120541.00280-2019
Year: 2020



A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes
Source: Eur Respir J, 59 (1) 2102603; 10.1183/13993003.02603-2021
Year: 2022



A data management and analysis platform for RASP-UK multiomics clinical datasets
Source: Virtual Congress 2021 – Exacerbations of chronic respiratory diseases, including SARS-CoV-2
Year: 2021